Search research articles
Contact Us
Filters
Showing results (61-70 of 112) with videos related to
Page
of 12
Sort By:
British Journal of Haematology
|
November 22, 2022
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial
Francis Mussai, Carmela De Santo, Paul Cheng, et al.
Leukemia
|
August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
Haematologica
|
November 28, 2015
Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors
Esteban Arrieta-Bolaños, Neema P Mayor, Steven G E Marsh, et al.
Blood
|
June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Steven Knapper, Abin Thomas, Robert K Hills, et al.
Haematologica
|
December 16, 2017
Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Xavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Blood Advances
|
December 24, 2019
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Emma Das-Gupta, Kirsty J Thomson, Adrian J C Bloor, et al.
Haematologica
|
August 4, 2009
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
Bella Patel, Keiren E Kirkland, Richard Szydlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 27, 2012
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Arnon Nagler, Myriam Labopin, Avichai Shimoni, et al.
Blood Advances
|
October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia
Paul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 112) with videos related to
Sort By:
Page
of 12
British Journal of Haematology
|
November 22, 2022
A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial
Francis Mussai, Carmela De Santo, Paul Cheng, et al.
Leukemia
|
August 21, 2024
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, et al.
Haematologica
|
November 28, 2015
Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors
Esteban Arrieta-Bolaños, Neema P Mayor, Steven G E Marsh, et al.
Blood
|
June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Steven Knapper, Abin Thomas, Robert K Hills, et al.
Haematologica
|
December 16, 2017
Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and <i>FLT3</i> internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Xavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Blood Advances
|
December 24, 2019
Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study
Emma Das-Gupta, Kirsty J Thomson, Adrian J C Bloor, et al.
Haematologica
|
August 4, 2009
Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission
Bella Patel, Keiren E Kirkland, Richard Szydlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 31, 2018
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D Freeman, Robert K Hills, Paul Virgo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 27, 2012
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Arnon Nagler, Myriam Labopin, Avichai Shimoni, et al.
Blood Advances
|
October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia
Paul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Page
of 12